4 Biopharma Stocks Likely to Move in October '24 Readouts
We used our BPIQ platform to identify biopharma stocks with major upcoming clinical readouts in October and are likely to move big. We found 4 of them! See the table and text below for more details, which are likely to be a big or a suspected mover, based on implied volatility data.
$CLSD
CLS-AX / Wet AMD (Age-Related Macular Degeneration) / Ph2b
CLS-AX is a tyrosine kinase inhibitor (TKI) with potential to treat VEGF-driven disorders such as wet AMD, DMA & DR. ODYSSEY Ph2b trial compare CLS-AX suprachoroidal injection & aflibercept intravitreal injection over 36 weeks. Topline data from this trial is expected in the week of Oct 7. Earlier, the Ph1/2a OASIS trial showed promising safety data, durability & biologic effect. 📸
$IMTX
ACTengine® IMA203 GEN1 (PRAME) / Melanoma / Ph1b
ACTengine® programs are based on genetically engineering a patient’s own, autologous T cells with novel TCRs designed to recognize the cancer target on the tumor. The engineered T cells (TCR-T) aim to induce a robust and specific anti-tumor attack to fight the cancer. Updated clinical data at SMR conference on 10/11.
$VSTM
Avutometinib +/- Defactinib / Low-Grade Serous Ovarian Cancer (LGSOC) / Ph2 ✔️
Avutometinib is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF, and CRAF potentially creating a durable anti-tumor response through maximal RAS/MAPK pathway inhibition. Late-breaking abstract of the mature RAMP 201 data at the IGCS Annual meeting in October.
$AMLX
AMX0035 / Wolfram syndrome / Ph2
AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol & designed to slow or mitigate neurodegeneration by targeting ER stress and mitochondrial dysfunction. HELIOS topline data for all 12 participants at Week 24 at ISPAD 2024 in October.
Footnote: ✔️ Confirmed by implied volatility data.
Want to see all smid cap biotech future movers in October?
Become a BPIQ Elite member & get the full list. We identify events that can drive significant price moves! 🚀
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 09/20/24 SK & EJV